期刊文献+

Contraceptive vaginal ring(NuvaRing)-a novel,convenient and effective contraceptive option

Contraceptive vaginal ring(NuvaRing)-a novel,convenient and effective contraceptive option
下载PDF
导出
摘要 Contraceptive vaginal ring(NuvaRing) is a new combined hormonal contraceptive method.Each ring contains 2.7mg ethinyl estradiol(EE) and 11.7mg etonogestrel.The ring is characteristic with its ease of use.lower EE systemic exposure and excellent cycle control.Studies have demonstrated that the efficacy and safety of the ring are equivalent to combined oral contraceptive(COC).The side effects of the ring are fewer and the biocompatibility is good.Recent studies have proved that the NuvaRing is a new,effective hormonal contraceptive option for women. Contraceptive vaginal ring (NuvaRing) is a new combined hormonal contraceptive method. Each ring contains 2.7mg ethinyl estradiol (EE) and 11.7mg etonogestrel. The ring is characteristic with its ease of use, lower EE systemic exposure and excellent cycle control. Studies have demonstrated that the efficacy and safety of the ring are equivalent to combined oral contraceptive (COC). The side effects of the ring are fewer and the biocompatibility is good. Recent studies have proved that the NuvaRing is a new, effective hormonal contraceptive option for women.
出处 《生殖医学杂志》 CAS 2011年第B12期79-84,共6页 Journal of Reproductive Medicine
关键词 避孕方法 阴道 选项 生物相容性 荷尔蒙 炔雌醇 安全性 COC Contraceptive vaginal ring Hormonal contraception Vaginal ring
  • 相关文献

参考文献29

  • 1Wieder DR,Pattimakiel L.Examining the efficacy,safety,and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).Int J Womens Health,2010,12:401-409.
  • 2Timmer CJ,Mulders TM.Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.Clin Pharmacokinet,2000,39:233-242.
  • 3van den Heuvel MW,van Bragt AJ,Alnabawy AK,et al.Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations:the vaginal ring,the transdermal patch and an oral contraceptive.Contraception,2005,72:168-174.
  • 4Roumen FJ,Dieben TO.Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of the contraceptive vaginal ring and an oral contraceptive.Fertil Steril,2006,85:57-62.
  • 5Mulders TM,Dieben TO,Bennink HJ.Ovarian function with a novel combined contraceptive vaginal ring.Hum Reprod,2002,17:2594-2599.
  • 6Duijkers IJ,Klipping C,Verhoeven CH,et al.Ovarian function with the contraceptive vaginal ring or an oral contraceptive:a randomized study.Hum Reprod,2004,19:2668-2673.
  • 7Barnhart KT,Timbers K,Pretorius ES,et al.In vivo assessment of NuvaRing placement.Contraception,2005,72:196-199.
  • 8Tarragón Gabarro S,Checa Vizcaino MA,Arango Toro O.Accidental introduction of a contraceptive vaginal ring into the urinary bladder.Int Urogynecol J Pelvic Floor Dysfunct,2009,20:1511-1513.
  • 9Roumen FJ,Apter D,Mulders TM,et al.Efficacy,tolerability and acceptability of a novel contraceptive vaginal ringreleasing etonogestrel and ethinyl oestradiol.Hum Reprod,2001,16:469-475.
  • 10Dieben T,Roumen F,Apter D.Efficacy,cycle control,and user acceptability of a novel combined contraceptive vaginal ring.Obstet Gynecol,2002,100:585-593.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部